U.S. markets open in 5 hours 23 minutes

Alterity Therapeutics Limited (ATHE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6400+0.0400 (+2.50%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.6000
Open1.6500
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range1.6150 - 1.7100
52 Week Range0.2800 - 5.1500
Volume964,998
Avg. Volume2,031,718
Market Cap35.368M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MarketWatch

    Alterity Therapeutics stock more than doubles on massive volume after new patent announcement

    The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6% on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, after the Australia-based drug maker announced the allowance of a new patent for next generation compounds to treat neurodegenerative diseases. Trading volume exploded to 61.3 million shares, making the stock the second-most active in the U.S., and compared with the full-day average of just about 81,000 shares. Alterity said the patent covers more than 150 novel pharmaceutical compositions that are designed to redistribute the labile iron implicated in neurodegenerative conditions including Parkinson's disease and Alzheimer's disease. "This broad patent establishes an excellent foundation for the company to pursue multiple therapeutics across a spectrum of neurodegenerative disease," said Chief Executive Geoffrey Kempler. The stock has soared 238.5% year to date, while the S&P 500 has gained 12.1%.

  • Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
    PR Newswire

    Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

    Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-house discovery research and is central to Alterity's next generation drug development portfolio focussed on neurodegenerative diseases.

  • Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
    PR Newswire

    Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

    Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States.